Overview

Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection

Status:
Not yet recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether ceftolozane-tazobactam is as effective as meropenem with respect to 30 day mortality in the treatment of bloodstream infection due to third-generation cephalosporin non-susceptible Enterobacterales or a known chromosomal AmpC-producing Enterobacterales (Enterobacter spp., Citrobacter freundii, Morganella morganii, Providencia spp. or Serratia marcescens).

Phase:

Phase 3

Details

Lead Sponsor:

The University of Queensland

Collaborators:

Merck Sharp & Dohme (Australia) Pty Limited
Merck Sharp & Dohme Corp.

Treatments:

Ceftolozane
Ceftolozane, tazobactam drug combination
Cephalosporins
Meropenem
Penicillanic Acid
Tazobactam